The expanding presence of the 340B Drug Pricing Program and implications of CMS's proposed CY 2027 OPPS rule

Product Service Form

Tampa

Hellems Sarah

Please enter a value less than 250 characters.

By clicking this box I acknowledge and consent that any personal data I enter in this form may be stored and processed by Milliman according to the terms of the <a href="https://au.milliman.com/privacy-policy" target="_blank" rel="noopener">Privacy Policy.</a> 

Please enter a message up 800 characters long.

There was a problem submitting your request.

Your message has been sent. We'll be in touch with you shortly.

Please enter a value up to 250 characters long.

Title

The form was not submitted. Please check fields and try again.

Sarah Hellems

Read their latest work

The expanding presence of the 340B Drug Pricing Program and implications of CMS's proposed CY 2027 OPPS rule

The expanding presence of the 340B Drug Pricing Program and implications of CMS's proposed CY 2027 OPPS rule

CHOOSE A LOCATION AND LANGUAGE